首页 | 本学科首页   官方微博 | 高级检索  
检索        

聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效的影响因素研究
引用本文:臧凤,姚轶男,刘梅,陈红波,黄鹏,喻荣彬.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效的影响因素研究[J].中华疾病控制杂志,2017,21(11):1157-1160.
作者姓名:臧凤  姚轶男  刘梅  陈红波  黄鹏  喻荣彬
作者单位:南京医科大学公共卫生学院流行病学系, 江苏 南京 211166
摘    要:目的 分析聚乙二醇干扰素联合利巴韦林(pegylated interferon plus ribavirin,pegIFN-α/RVB)治疗慢性丙型肝炎(chronic hepatitis C,CHC)疗效的影响因素,以便辅助判断治疗效果及合理变换治疗方案。方法 收集来自江苏省句容市人民医院CHC临床治疗患者的基线资料,采用单因素及多因素Logistic回归进行分析。结果 本研究纳入371例CHC患者,总持续性病毒学应答(sustained virological response,SVR)率为64.7%。多因素Logistic回归分析结果显示,基线病毒载量HCV RNA高(OR=0.95,95%CI:0.91~0.99,P=0.012)、甲胎蛋白(alpha fetoprotein,AFP)水平异常(OR=0.87,95%CI:0.78~0.97,P=0.014)及空腹血糖(blood glucose,GLU)水平异常(OR=0.86,95%CI:0.78~0.95,P=0.004)者更不易获得SVR。结论 pegIFN-α/RVB治疗CHC患者的SVR率较高,基线病毒载量、AFP及GLU均是影响持续病毒学应答的危险因素。

关 键 词:肝炎  丙型  慢性    治疗效果    利巴韦林
收稿时间:2017-03-22

Study on the influencing factors of interferon/ribavirin in patients with chronic hepatitis C
ZANG Feng,YAO Yinan,LIU Mei,CHEN Hong-bo,HUANG Peng,YU Rong-bin.Study on the influencing factors of interferon/ribavirin in patients with chronic hepatitis C[J].Chinese Journal of Disease Control & Prevention,2017,21(11):1157-1160.
Authors:ZANG Feng  YAO Yinan  LIU Mei  CHEN Hong-bo  HUANG Peng  YU Rong-bin
Institution:Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China
Abstract:Objective To analyze the baseline influencing factors of pegylated interferon plus ribavirin (pegIFN-α/RVB) in the treatment of chronic hepatitis C (CHC) in order to help to judge the therapeutic effect and the reasonable treatment plan.Methods The baseline data of CHC patients in Jurong People's Hospital of Jiangsu Province were collected and analyzed by univariate and multivariate Logistic regression.Results A total of 371 patients with hepatitis C was surveyed.The total SVR rate was 64.7%.Multivariate logistic regression analysis showed that high baseline viral load of HCV RNA (OR =0.95,95% CI:0.91-0.99,P =0.012),abnormal alpha fetoprotein (AFP) level (OR =0.87,95% CI:0.78-0.97,P =0.014) and abnormal fasting blood glucose (GLU) level (OR =0.86,95 % CI:0.78-0.95,P =0.004) were less likely to get SVR.Conclusions The SVR rate was higher in the treatment of pegIFN-α/RVB with CHC patients.Baseline viral load,AFP and GLU are the factors affecting the sustained virological response after treatment.
Keywords:Hepatitis C  chronic  Treatment outcome  Ribavirin
本文献已被 万方数据 等数据库收录!
点击此处可从《中华疾病控制杂志》浏览原始摘要信息
点击此处可从《中华疾病控制杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号